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Summary
Purpose: P-glycoprotein 170 encoded by the multidrug resistance 1 (MDR1) gene
exports various antiepileptic drugs out of the CNS, which leads to multidrug resis-
tance. This study was performed to elucidate the relationship between single
nucleotide polymorphisms (SNPs) in the MDR1 gene and drug resistance in Koreans
with epilepsy.
Subjects and methods: Three SNPs at nucleotide position 1236 in exon 12, 2677 in
exon 21 and 3435 in exon 26 of the MDR1 gene were genotyped in 207 Korean
epileptics. Subjects were classified according to whether they had drug-resistant (RS
group; N = 99) or drug-responsive epilepsy (RP group; N = 108). The frequencies of
genotype and haplotype were compared between the RS and RP groups.
Results: The frequencies of genotype and haplotype in the RS group were not
statistically different from those in the RP group.
Conclusions: In Korean epileptics, there was no significant relationship between
three known SNPs in MDR1 and drug resistance. And there was no association of
MDR1 haplotype based on above three sites with pharmacoresistance.
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Drug-resistant epilepsy causes recurrent convulsions
and side-effects that are related to the use of
multiple drugs, which sometimes result in death.
Drug-resistant epilepsy is estimated to affect about
30% of the epileptic population despite the avail-
ability of several newly developed antiepileptic
drugs.1 Although efforts to predict pharmacoresis-
tance have revealed several risk factors,1,2 the
mechanism of resistance remains unknown.
Recently, a genetic approach to studying drug-resis-
tant epilepsy raised the possibility that the patho-
genic mechanism of pharmacoresistance in epilepsy
might be revealed, which would facilitate the treat-
ment of drug-resistant epilepsy.3—5
Pharmacogenetic assessments of drug-resistant
epilepsy4 have focused on drug-metabolizing
enzymes, such as the cytochrome P450 family of
enzymes; drug transporters, such as multidrug resis-
tance transporters; and drug targets. Transporter
proteins play an important role in drug disposition.
Among these proteins, P-glycoprotein 170, which is
the product of the ATP-binding cassette subfamily b
member 1 (ABCB1), also known as the multidrug
resistance 1 (MDR1) gene, is the most extensively
studied.4 P-glycoprotein 170 is an energy-depen-
dent efflux pump that exports several antiepileptic
drugs,4,6 including carbamazepine,7 phenytoin,8
phenobarbital, lamotrigine, and felbamate.9
Single nucleotide polymorphisms (SNPs) in the
MDR1 gene have been described, including
T1236C in exon 12, G2677T/A in exon 21, and
C3435T in exon 26. These SNPs have been reported
to confer drug resistance upon patients with various
diseases.10—12 Initially, Siddiqui et al.3 studied the
association between multidrug-resistant epilepsy
and the C3435T polymorphism. They demonstrated
that patients with drug-resistant epilepsy were
more likely to have the CC than the TT genotype,
although the frequency of the CT genotype did not
differ significantly between patients with drug-
resistant epilepsy and patients with drug-responsive
epilepsy.3 However, similar consecutive studies by
Tan et al.13 and Sills et al.14 failed to corroborate
this association3 between the C3435T polymorphism
in the human MDR1 gene and pharmacoresistant
epilepsy.
As previous studies of MDR1 polymorphisms in
normal volunteers revealed significant differences
in the genotype or allele frequencies among differ-
ent ethnic groups,15—17 studies such as that of Sid-
diqui et al.3 should be replicated in other ethnic
groups, especially in Asian populations with geno-
type frequencies that differ from those of Cauca-
sians. The present study was performed to elucidatethe relationship between MDR1 SNPs and drug resis-
tance in Korean epileptics.Subjects and methods
Subjects
Approximately 400 patients who had been diagnosed
at three different epilepsy clinics (ChonnamNational
University Hospital, Mirae Children’s Hospital, and
Gwangju Christian Hospital, Gwangju, Korea) were
recruited for the studyover 5months (June—October,
2004) to elucidate the relationship between the
MDR1 SNPs and drug-resistant epilepsy. The research
review board of Chonnam National University Hospi-
tal (Gwangju, Korea) approved the study, and all of
subjects provided informed consent. Medical records
were reviewed retrospectively for responsiveness to
antiepileptic drugs by neurologists and pediatric
neurologists at the three epilepsy clinics. Among this
initial group, 207 patients who met the criteria
described below were enrolled. Patients with drug-
resistant epilepsy (60 men plus 39 women; median
age = 15 years; range = 2—51 years) were classified
into the RS group, while patients with drug-respon-
sive epilepsy (57 men plus 51 women; median
age = 13 years; range = 3—62 years) were classified
into the RP group.
Drug resistance was defined as the occurrence of
at least four seizures during the previous year for
patients who were being treated with more than
two primary antiepileptic drugs at the maximally
tolerable daily doses. Cases of pseudorefractory
epilepsy that resulted from inappropriate drug
selection or poor compliance with medication were
excluded. Subjects who had undergone surgical
treatment for drug-resistant epilepsy were classi-
fied as exhibiting drug resistance irrespective of the
outcome of the surgery. Drug responsiveness was
defined as a complete absence of seizures for at
least 1 year prior to the date of the latest follow-up
visit.
Genotyping of SNP sites in the MDR1 gene
To obtain genomic DNA, blood samples were drawn
after obtaining informed consent from the patient
(or guardian in the case of a child). Genomic DNA
was isolated from the blood using standard
methods.
Three known polymorphic sequences in the MDR1
gene were amplified by polymerase chain reaction
(PCR). The index polymorphic sequence strings were
identified in exons 12 (nucleotide position 1236), 21
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Table 1 Genotyping of polymorphic sequence strings of MDR1
Nucleotide position Exon Nucleotide sequence 50 primer 30 primer
Wild type Mutant type
1236 12 agggTctga agggCctga 50 ATCCTGTGTC
TGTGAATTGC 30
50 TCAGAAAGATGT
GCAATGTG 30
2677 21 aggtGctgg aggtActgg 50 TCAGAAAATAG
AAGCATGAGTTG 30
50 AGCAGTAGGGAG
TAACAAAATAAC 30aggtTctgg
3435 26 agatCgtga agatTgtga 50ACATTCAAAGTGT
GCTGGTC 30
50 ACTATAGGCCAG
AGAGGCTG 30(2677), and 26 (3435) (Table 1). Appropriate forward
and reverse primer sets for each string were pre-
pared (Table 1), and PCR was carried out under the
following conditions. Genomic DNA (100—300 ng)
was amplified in a volume of 50 ml of enzyme storage
buffer B (Promega, USA), 10 pmol of each primer,
2.5 mM MgCl2, 200 mM deoxynucleotide tripho-
sphates, and 1.25 units of Taq DNA polymerase
(Promega). The PCR conditions were as follows:
an initial denaturation step at 95 8C for 5 min,
followed by 45 cycles of denaturation at 95 8C for
30 s, annealing for 45 s at 55 8C for exon 12, 56 8C for
exon 21, and 57 8C for exon 26, an extension step at
72 8C for 1 min, and a final extension step at 72 8C
for 7 min. The PCR products were analyzed on stan-
dard 2% agarose gels stained with ethidium bromide
(0.5 mg/ml). All of the purified PCR products were
sequenced directly using BigDye Terminator Chem-
istry (PE Biosystems, USA), and three sites in the
MDR1 sequence were inspected.
While PCR amplification of the MDR1 SNPs in
the present study was successful in most cases, some
of the PCR products were inadequate and were
excluded from the initial analysis (i.e., for position
1236 in exon 12, two PCR products in the RS group
and one in the RP group; for position 2677 in exon
21, one in the RP group; and for position 3435 in
exon 26, eight in the RP group).
Statistical analysis
Deviations of genotype frequencies
The genotype frequencies at each nucleotide posi-
tion in MDR1 were assessed for deviations from
Hardy—Weinberg equilibrium using the x2-test
in the population genetics data analysis program
Popgen32.
Comparisons of genotype and haplotype
frequencies
The genotype and haplotype frequencies were com-
pared between the RS and RP groups using the
Pearson x2-test. If the minimum expected count
was <5, Fisher’s exact test was used to comparethe frequencies. Logistic regression with reference
to the RP group was used to estimate the potential
influence of each genotype on the degree of phar-
macoresistance. Statistical significance was
accepted as P < 0.05. The SPSS 11.0 and MedCalc
7.4 programs were used for these analyses.
Estimation of haplotype frequencies
Samples in which at least one locus could not be
genotyped were excluded from the haplotype fre-
quency calculation (i.e., two samples in the RS
group and nine in the RP group).
The haplotype frequencies were estimated based
on an expectation maximization (EM) algorithm,
leading to maximum-likelihood estimates of mole-
cular haplotype frequency under the assumption of
Hardy-Weinberg proportions.18 The EM algorithm
estimated the haplotype frequencies from the gen-
otype data. An EM linkage utility program was used
to estimate the haplotype frequencies.Results
Genotype frequencies of MDR1 SNPs and
drug responsiveness
Three different genotypes, TT, TC, and CC, were
identified at position 1236 in exon 12 (Table 2).
There were no significant deviations from Hardy—
Weinberg equilibrium in any group (for the RS group,
x2/P-value = 1.76/0.18; for the RP group, x2/P-
value = 0.19/0.66). The genotype frequencies of
TT, TC and CC are listed in Table 2. The genotype
frequencies in the RS group were not statistically
different from those in the RP group.
Six different genotypes, GG, GT, GA, TA, TT, and
AA, were identified at position 2677 in exon 21
(Table 3). There were no significant deviations from
Hardy—Weinberg equilibrium in any group (for the
RS group, x2/P-value = 2.08/0.56; for the RP group,
x2/P-value = 3.40/0.33). For the RS versus RP
groups, the frequencies of each genotype are listed
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Table 3 Genotype frequencies at nucleotide site 2677 in exon 21 of MDR1
Genotype Genotype frequency, N (%) P value Odds ratio 95% C.I.
RS [N, 99] RP [N, 107]
GG 19 (19.2) 17 (15.9) 0.66 1.26 0.61—2.58
GT 33 (33.3) 40 (37.4) 0.64 0.84 0.47—1.48
GA 22 (22.2) 21 (19.6) 0.77 1.17 0.60—2.29
TA 12 (12.1) 15 (14.0) 0.84 0.85 0.37—1.91
TT 11 (11.1) 9 (8.4) 0.68 1.36 0.54—3.44
AA 2 (2.0) 5 (4.7) 0.49 0.42 0.08—2.22
N, total number; RS, patients with drug-resistant epilepsy; RP, patients with drug-responsive epilepsy.
Table 2 Genotype frequencies at nucleotide position 1236 in exon 12 of MDR1
Genotype Genotype frequency, N (%) P value Odds ratio 95% C.I.
RS [N, 97] RP [N, 107]
TT 39 (40.2) 36 (33.6) 0.41 1.32 0.75—2.35
TC 40 (41.2) 54 (50.5) 0.23 0.69 0.40—1.20
CC 18 (18.6) 17 (15.9) 0.75 1.21 0.58—2.50
N, total number; RS, patients with drug-resistant epilepsy; RP, patients with drug-responsive epilepsy.in Table 3. The genotype frequencies in the RS group
were not statistically different from those in the RP
group.
Three different genotypes, CC, CT, and TT,
were identified at position 3435 in exon 26
(Table 4). There were no significant deviations
from Hardy—Weinberg equilibrium in any group
(for the RS group, x2/P-value = 1.47/0.23; for
the RP group, x2/P-value = 1.49/0.22). The geno-
type frequencies in the RS group were not statis-
tically different from those in the RP group, as
shown in Table 4.
Haplotype frequencies of MDR1 SNPs and
drug responsiveness
The haplotype frequencies estimated from the gen-
otype data were compared between the two groups
(Table 5). There were 12 possible MDR1 haplotypes
and the frequencies of each of the MDR1 haplotypes
were not statistically different between the two
groups.Table 4 Genotype frequencies at nucleotide site 3435 in e
Genotype Genotype frequency, N (%)
RS [N, 99] RP [N, 100]
CC 47 (47.5) 45 (45.0)
CT 46 (46.5) 48 (48.0)
TT 6 (6.1) 7 (7.0)
N, total number; RS, patients with drug-resistant epilepsy; RP, patDiscussion
The brain is protected by a unique barrier called the
blood—brain barrier (BBB). But the BBB represents a
serous obstacle in achieving appropriate drug con-
centrations in the CNS.19 The P-glycoprotein of an
efflux transporter in the BBB is a 170-kDa transmem-
brane phosphoglycoprotein that is encoded by the
MDR1 gene, which is located on chromosome 7 and
consists of 28 exons.6,20 The P-glycoprotein expres-
sion levels in different tissues are not constant, but
rather change in response to various agents and
environmental factors.20 In epileptics, P-glycopro-
tein is overexpressed in endothelial cells of the BBB
and is expressed at sites at which P-glycoprotein is
not expressed in normal subjects, e.g., in astrocytes
and neurons.21—23
Mutations in MDR1 influence the expression or
function of P-glycoprotein in normal tissues.24
Approximately 28 SNPs have been identified in
MDR1, among which the SNPs of T1236C in exon
12, G2677A/T in exon 21, and C3425T in exon 26 are
the most commonly reported in normal subjectsxon 26 of MDR1
P value Odds ratio 95% C.I.
0.83 1.10 0.63—1.93
0.94 0.94 0.54—1.64
0.98 0.86 0.28—2.65
ients with drug-responsive epilepsy.
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Table 5 Haplotype frequencies of three single nucleotide polymorphisms in the MDR1 gene
Haplotype Haplotype frequency (%) P value Odds ratio 95% C.I.
T1236C G2677T/A C3435T RS [N, 97] RP [N, 99]
T G C 20.78 19.49 0.96 1.09 0.54—2.21
T G T 1.07 4.68 0.28 0.20 0.02—1.71
T T C 10.40 9.13 0.95 1.15 0.45—2.96
T T T 17.12 15.74 0.95 1.10 0.52—2.33
T A C 1.06 0.59 0.67 1.02 0.06—16.56
T A T 10.40 8.95 0.92 1.15 0.45—2.96
C G C 19.91 17.24 0.77 1.18 0.57—2.42
C G T 0.00 0.00
C T C 16.54 16.12 0.91 1.02 0.48—2.19
C T T 0.79 1.44 0.80 1.02 0.06—16.56
C A C 1.94 6.62 0.21 0.28 0.06—1.37
C A T 0.00 0.00
N, total number; RS, patients with drug-resistant epilepsy; RP, patients with drug-responsive epilepsy.from different ethnic groups.15—17 The G2677A/T
SNP in exon 21 is usually associated with an amino
acid conversion from Ala to Thr and to Ser, respec-
tively.15 On the other hand, the T1236C SNP in exon
12 is located in non-coding regions and the C3435T
SNP in exon 26 does not lead to a change in the
amino acid sequence.15 Nevertheless, silent SNPs
may play important roles in drug resistance, since
they may be in linkage disequilibrium with non-
silent SNPs.3,15,25
The mutation at nucleotide position 3435 in exon
26 of MDR1 is the most frequently studied poly-
morphism in relation to multidrug resistance.3,10—
12 Siddiqui et al.3 have reported an association
between multidrug resistance in epileptics and
the C3435T polymorphism in the drug transporter
gene ABCB1. These authors demonstrated that
patients with drug-resistant epilepsy had a higher
frequency of the CC genotype (27.5%) in comparison
with drug-responsive epileptics or nonepileptic con-
trols (15.7 or 18.5%, respectively) and a lower fre-
quency of the TT genotype (19.5, 29.6, and 23.5%
for drug-resistant epileptics, drug-responsive epi-
leptics, and controls, respectively).3 Although Sid-
diqui et al.3 included Caucasian and Asian patients
in their study (187 versus 13 in the drug-resistant
group; 110 versus 5 in the drug-responsive group,
respectively), the authors suggested that the results
were similar when the analysis was restricted to the
Caucasian patients. In contrast to the results of
Siddiqui et al.,3 Tan et al.13 (subjects: 98.5% Cau-
casians in a total population of 609 persons) and Sills
et al.14 (subjects: 400 Caucasians in Scotland)
showed no significant association between the CC
genotype and drug-resistant epilepsy. In addition,
we failed to find any differences in genotype fre-
quencies between Koreans with drug-resistant and
drug-responsive epilepsy. As Tan et al.13 regardedthe initial positive study3 as having a tendency to
overestimate effect size, their subsequent replica-
tion attempts involved larger sample sizes (401
drug-resistant and 208 drug-responsive subjects).
Although the current study also involves low num-
bers of subjects, it replicates the previous study
carried out by Siddiqui et al.3 in showing that Asians
(Koreans only) have a different linkage disequili-
brium than Caucasians.
The mutations at nucleotide position 2677 in
exon 21 and at nucleotide position 1236 in exon
12 of MDR1 confer drug resistance in several dif-
ferent disease states, although the data available
for epilepsy are insufficient.10—12 In addition, for
the haplotype analysis based on polymorphisms at
the above three sites, only some of the data are
relevant to epilepsy.26,27 Although our study in
Koreans lacks sufficient sample size to avoid ana-
lysis bias and needs to be corroborated in other
ethnic groups, it reveals no differences in the gen-
otype and haplotype frequencies for these three
SNPs between patients with drug-resistant and
drug-responsive epilepsy. Despite these negative
results, the importance of these SNPs cannot be
ignored, as they may be in linkage disequilibrium
with causal variants.
The identification of mutations in the MDR1 gene
is expected to result in the prediction of therapeutic
outcomes and improvements in therapeutic effi-
cacy, although SNPs or mutations alone cannot
explain these factors.3,12 In patients who exhibit
predicted drug resistance, a more intensive treat-
ment regimen combined with the administration of
P-glycoprotein inhibitors may be applied. Moreover,
MDR1 mutations may reveal the characteristics of
specific MDR1 variants, which could lead to the
development of inhibitors that are specific for indi-
vidual variants.12
72 Y.O. Kim et al.Studies such as ours and that of Siddiqui et al.3
have been carried out under the assumptions that
SNPs in MDR1 influence responses to antiepileptic
drugs and that a direct relationship exists between
theMDR1 genotype and the MDR1 expression level in
the brain. Even though these assumptions remain to
be substantiated, future studies of surgical cases
will allow these issues to be addressed.
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